Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- MHLW’s Council to Draw Up 10-Year Strategy for Hepatitis
September 9, 2011
- Council Recommends Subsidization of Peginterferon Therapy for Chronic Active Hepatitis B
September 9, 2011
- CSIMC Recommends NHI Price Listing for 15 APIs/20 Products
September 8, 2011
- Generic Dispensing Not Promoted in Pharmacies: CSIMC’s Subcommittee
September 8, 2011
- CSIMC Introduces New Rule for Pricing of High-Priced Drugs; 10 Drugs to Be Reimbursed on Piecework under DPC
September 8, 2011
- Some CSIMC Members Question NHI Pricing of Nexium Priced at Lower Level Than Omepral
September 8, 2011
- CSIMC Recommends NHI Price Listing for 15 APIs/20 Products
September 7, 2011
- MHLW Senior Vice Minister Tsuji, Parliamentary Secretary Fujita in Charge of Medical, Nursing Fee Revision
September 7, 2011
- Dr Kondo of PMDA Presents Example of Successful Use of Regulatory Science
September 6, 2011
- Pharmaceutical Industry Fully Sufficient as Export Industry: METI Minister Hachiro
September 5, 2011
- MHLW Minister Komiyama to Focus on Social Security Reform
September 5, 2011
- Noda Cabinet: MHLW Vice Minister Komiyama Promoted to Minister
September 5, 2011
- Korosho to Apply for PIC/S Membership in Early FY2012: New CND Director Nakaigawa
September 5, 2011
- New EAD Director Kamata Supports Making Premium for New Drug Development Permanent
September 5, 2011
- METI to Establish New Company to Support Medical Tourism from Overseas
September 5, 2011
- Avastin Recommended for Approval for Breast Cancer
September 5, 2011
- Fingolimod Recommended for Approval
September 5, 2011
- Make the Premium for New Drug Development Permanent: FPMAJ, PhRMA, EFPIA Japan
September 5, 2011
- Increases in Social Security Spending to Be Covered by Cuts in Other Spending: FY2012 Budget
September 5, 2011
- US FDA Approves Vemurafenib for Melanoma; to Be Copromoted by Daiichi Sankyo
September 5, 2011
ページ
Japan’s health and finance ministers agreed late last year to go ahead with an “off-year” drug price revision in FY2027,…
The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…